Broange
ls Indicated in:
-
Multiple Myeloma
- Mantle Cell Lymphoma.
Strengthening
New Hope
Expert's View
- Bortezomib is novel antimyeloma agent that has a direct beneficial effect on bone formation
- Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation
- VR-CAP ( Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone ) was more effective than R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed mantle-cell lymphoma
-
PFS (progression-free survival) and 08 (overall survival) wereprolonged in patients who received VMP( Bortezomib, melphalan, prednisone) in comparison with those treated with MPT (melphalan, prednisone, thalidomide)
- Bortezomib-based therapy after autologous stem cell transplantation, with tolerable AEs, could obviously improve the response as well as the outcome of multiple myeloma patients, particularly when bortezomib was administered as maintenance therapy
- Bortezomib-based induction results in significant improvements in response and PFS/OS compared with non bortezomib-based induction and is generally well tolerated
- Bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT ( allogeneic hematopoietic stem cell transplantation)
